In 2017, the thirty-year-long pioneering diabetes study at the University of Tampere progressed to a new phase. The research group led by Heikki Hyöty, professor of virology, had previously identified enteroviruses associated with diabetes, and the prototype vaccine developed to combat them was found to be safe and effective in mice. In the summer, it was announced that the vaccine study will progress to the human trial phase when the Tampere firm Vactech Oy and the US company Provention Bio were able to arrange the necessary funding. Human trials are due to begin in 2020. The world’s largest foundation for the development of diabetes research, the Juvenile Diabetes Research Foundation (JDRF), is also a co-operation partner.